HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Previous close
$5.03
Day range
$5.02 - $5.05
Year range
$1.81 - $5.06
Market cap
45.52M USD
Avg Volume
90.41K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 100.00K | -90.00% |
Operating expense | 3.18M | -46.56% |
Net income | -2.95M | 35.92% |
Net profit margin | -2.95K | -540.78% |
Earnings per share | — | — |
EBITDA | -3.06M | 37.57% |
Effective tax rate | 0.00% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 15.96M | -48.93% |
Total assets | 17.74M | -49.31% |
Total liabilities | 3.14M | -44.71% |
Total equity | 14.60M | — |
Shares outstanding | 9.03M | — |
Price to book | 2.99 | — |
Return on assets | -38.97% | — |
Return on capital | -48.53% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -2.95M | 35.92% |
Cash from operations | -3.25M | 28.25% |
Cash from investing | 0.00 | -100.00% |
Cash from financing | 205.00K | 313.54% |
Net change in cash | -3.04M | 7.82% |
Free cash flow | -3.58M | -21.34% |
About
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Founded
1980
Headquarters
Website
Employees
26
